Fig. 3From: A prospective, open-label, non-comparative study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosisPulmonary Function Tests (PFTs) at 0, 6 and 12 months since initiation of ambrisentanBack to article page